Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-380-4 | CAS number: -
Endpoint summary
Administrative data
Key value for chemical safety assessment
Additional information
The bacterial reverse mutation assay / Ames test (Thompson_2008) performed according to OCED 471 was rated with RL=1 (reliable without restrictions) and used as a key study. The study had a negative result. The results indicate that SymMollient® S under the experimental conditions described (concentration range in the main test: experiment I: 0, 0.15, 0.5, 1.5, 5, 15, 50, 150, 500, 1500 and 5000 µg/plate and experiment II: 50, 150, 500, 150 and 5000 µg/plate), is not mutagenic to Salmonella typhimurium strains TA1535, TA1537, TA98, TA100, and TA 102 in the presence and absence of a metabolizing system.
The mammalian cell gene mutation assay (Hall_2010) performed according to OECD 476 was rated with RL=1 (reliable without restrictions) and used as a key study. The study had a negative result. The results indicate that SymMollient® S under the experimental conditions described did not induce mutation at the hprt locus in Chinese hamster lung fibroblasts (V79). These conditions included treatments up to a maximum concentration of ca. 10 mM (3915.0 µg/mL) in two independent experiments in the absence and presence of a rat liver metabolic activation system (S9 mix).
The in-vitro mammalian chromosome aberration test (Bohnenberger_2010) performed according to OCED 473 was rated with RL=1 (reliable without restrictions) and used as a key study. The study had a negative result. The test item SymMollient® S did not induce structural chromosomal aberrations in human lymphocytes. Therefore, SymMollient® S is considered to be non-clastogenic in the chromosome aberration test when tested up to the highest concentration of 10 mM (3915.0 µg/mL) with and without metabolic activation (S9 mix).
Short description of key information:
In-vitro studies:
Bacterial reverse mutation assay / Ames test (OECD 471) - k_Thompson_2008: negative
Mammalian cell gene mutation assay (OECD 476) - k_Hall_2010: negative
Mammalian chromosome aberration test (OECD 473) - k_Bohnenberger_2010: negative
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
All available reliable studies showed no genetic toxicity for SymMollient® S. Thus, no classification is required for the time being according to Regulation 1272/2008 and subsequent regulations.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
